MaterniT21 Plus
Use
The MaterniT21 PLUS test analyzes circulating cell-free DNA extracted from a maternal blood sample. The test is intended for use in pregnant women at increased risk for chromosomal aneuploidies such as trisomy 21, 18, and 13, along with determining the sex of the fetus. It is a non-invasive prenatal screening test that offers valuable information regarding the genetic health of the fetus. This test is not diagnostic but provides insights that could guide further invective testing in a clinical setting. It is significant for pregnancies at increased risk for chromosomal conditions and can guide management through early detection.
Special Instructions
Not provided.
Limitations
This test is not intended to detect pregnancies at risk for neural tube defects or ventral wall defects. While it is highly accurate, not all chromosomal abnormalities may be detected due to factors such as placental, maternal, or fetal mosaicism. It does not replace the precision of prenatal diagnosis made through procedures like CVS or amniocentesis. Validation data for multiple pregnancies like twin or triplet gestations is limited. A negative test result does not ensure an unaffected pregnancy. Positive results should prompt further genetic counseling and potential confirmatory invasive testing.
New York Approved
Methodology
NGS
Biomarkers
Result Turnaround Time
7-14 days
Related Documents
For more information, please review the documents below
Specimen
Whole Blood
Volume
10 mL
Minimum Volume
10 mL
Container
Streck tube
Collection Instructions
Draw 1 tube of blood, 10 mL in special Streck tube kit (MCL supply number T715). Ship ambient.
Patient Preparation
Specimen collected NOT less than 9 weeks of gestation
Storage Instructions
Specimen MUST be received at MCL within 72 hours of collection.
Causes for Rejection
Gross hemolysis
Stability Requirements
| Temperature | Period |
|---|---|
| Room Temperature | 7 days |